$2.37
Codexis
Performance
Dividends
1W
1M
YTD
1Y
3Y
11/36
Growth
Score
8/36
Dividend
Score
Valuation
PE Ratio
-3.11
PS Ratio
3.33
RSI
-
0
PEG Ratio
-0.03
0
PRG Ratio
-0.04
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
78.17%
3
Gross Margin
77.61%
3
Current Ratio
5.82
Return on Assets
-47%
Return on Equity
-105.83%
Return on inv. Capital
-784.92%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 59.34M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -65.28M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 43.06M
2018
2019
2020
2021
2022
2023
2024
6
Events
CDXS
Codexis
in 186 days
after market close
Earnings per Share is expected with - and revenue with - .
CDXS
Codexis
in 110 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
22.04.2010
MaketCap
190.28M
Country
US
CEO
Stephen George Dilly MBBS,
Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Updated 03.11.2025